George Poste Sells 30,000 Shares of Exelixis, Inc. (NASDAQ:EXEL) Stock

Exelixis, Inc. (NASDAQ:EXEL) Director George Poste sold 30,000 shares of the company’s stock in a transaction that occurred on Friday, November 1st. The stock was sold at an average price of $34.00, for a total value of $1,020,000.00. Following the transaction, the director now directly owns 169,020 shares in the company, valued at approximately $5,746,680. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

George Poste also recently made the following trade(s):

• On Thursday, August 8th, George Poste sold 33,725 shares of Exelixis stock. The stock was sold at an average price of $26.89, for a total value of $906,865.25.

Exelixis Trading Up 0.8 %

NASDAQ:EXEL opened at $35.80 on Friday. The firm’s 50 day moving average is $27.87 and its 200 day moving average is $24.64. Exelixis, Inc. has a 12 month low of $19.20 and a 12 month high of $36.17. The stock has a market capitalization of $10.22 billion, a PE ratio of 22.95, a price-to-earnings-growth ratio of 0.87 and a beta of 0.51.

Exelixis (NASDAQ:EXEL) last posted its quarterly earnings results on Tuesday, October 29th. The biotechnology company reported $0.40 earnings per share for the quarter, topping the consensus estimate of $0.36 by $0.04. Exelixis had a return on equity of 20.99% and a net margin of 22.43%. The company had revenue of $539.50 million during the quarter, compared to the consensus estimate of $490.31 million. During the same quarter in the prior year, the company earned $0.10 EPS. The firm’s quarterly revenue was up 14.3% compared to the same quarter last year. Research analysts predict that Exelixis, Inc. will post 1.68 earnings per share for the current year.

Wall Street Analysts Forecast Growth

EXEL has been the subject of a number of recent research reports. Morgan Stanley upped their price objective on shares of Exelixis from $26.00 to $28.00 and gave the stock an “equal weight” rating in a report on Friday, October 11th. HC Wainwright restated a “buy” rating and issued a $29.00 target price on shares of Exelixis in a report on Wednesday, September 18th. Piper Sandler lifted their price target on Exelixis from $33.00 to $36.00 and gave the company an “overweight” rating in a research note on Wednesday, October 30th. BMO Capital Markets increased their price objective on Exelixis from $29.00 to $36.00 and gave the stock an “outperform” rating in a research note on Wednesday, October 30th. Finally, Stifel Nicolaus lifted their target price on Exelixis from $26.00 to $30.00 and gave the company a “hold” rating in a research report on Wednesday, October 16th. One analyst has rated the stock with a sell rating, five have assigned a hold rating, fourteen have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $31.44.

Institutional Trading of Exelixis

Hedge funds and other institutional investors have recently modified their holdings of the business. Farallon Capital Management LLC grew its stake in Exelixis by 1.6% in the 2nd quarter. Farallon Capital Management LLC now owns 27,102,500 shares of the biotechnology company’s stock valued at $608,993,000 after buying an additional 424,000 shares in the last quarter. Renaissance Technologies LLC grew its position in shares of Exelixis by 0.4% in the second quarter. Renaissance Technologies LLC now owns 15,163,066 shares of the biotechnology company’s stock valued at $340,714,000 after purchasing an additional 61,350 shares in the last quarter. LSV Asset Management raised its stake in shares of Exelixis by 107.7% during the 2nd quarter. LSV Asset Management now owns 5,763,728 shares of the biotechnology company’s stock valued at $129,511,000 after purchasing an additional 2,989,021 shares during the period. Dimensional Fund Advisors LP lifted its holdings in Exelixis by 7.3% during the 2nd quarter. Dimensional Fund Advisors LP now owns 5,137,201 shares of the biotechnology company’s stock worth $115,434,000 after purchasing an additional 349,837 shares in the last quarter. Finally, AQR Capital Management LLC boosted its stake in Exelixis by 12.7% in the 2nd quarter. AQR Capital Management LLC now owns 3,281,578 shares of the biotechnology company’s stock worth $73,425,000 after purchasing an additional 370,199 shares during the period. Institutional investors own 85.27% of the company’s stock.

Exelixis Company Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.